Previous close | 5.62 |
Open | 5.59 |
Bid | 5.61 x 800 |
Ask | 5.99 x 800 |
Day's range | 5.59 - 5.95 |
52-week range | 3.10 - 7.50 |
Volume | |
Avg. volume | 16,069 |
Market cap | 34.844M |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.11 |
Earnings date | 08 Nov 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 22.75 |
ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical Officer, Dr. Peter Staats will host an analyst day entitled “Accessing the Power of Vagus Nerve Stimulation with gammaCore™” on November 21, 2023 at 1:30pm EST. The webinar will cover the nVNS mechanism of action and potential pipeline of indications using the company’s proprietary nVNS technology plat
electroCore, Inc. (NASDAQ:ECOR) Q3 2023 Earnings Call Transcript November 8, 2023 electroCore, Inc. misses on earnings expectations. Reported EPS is $-0.68 EPS, expectations were $-0.64. Operator: Greetings, and welcome to the electroCore Third Quarter 2023 Earnings Conference Call. At this time, all participants on a listen only mode. Please make sure to mute yourself. A […]
Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5 million Company to host a conference call and webcast today, November 8, 2023 at 4:30 PM EST ROCKAWAY, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced third quarter 2023 financial results and prov